Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | KITE-222 |
Synonyms | |
Therapy Description |
KITE-222 comprises autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets CLL1, potentially resulting in increased toxicity in CLL1-expressing tumor cells (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
KITE-222 | KITE 222|KITE222 | KITE-222 comprises autologous T-cells engineered to express a chimeric antigen receptor (CAR) that targets CLL1, potentially resulting in increased toxicity in CLL1-expressing tumor cells (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05041309 | Phase II | KITE-585 KITE-222 Brexucabtagene autoleucel KITE-718 axicabtagene ciloleucel KITE-439 | Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells | Enrolling by invitation | USA | NLD | ISR | GBR | FRA | DEU | CAN | AUS | 1 |